Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06968663 · ClinicalTrials.gov registry record · Phase 2
Transcranial Magnetic Stimulation + Language Therapy to Treat Subacute Aphasia
A Phase 2 study of Stroke and Aphasia, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
- 1
- Study location
NCT06968663: Recruiting Phase 2 study of Stroke and Aphasia, sponsored by University of Pennsylvania.
NCT06968663 is a Phase 2 study of Stroke and Aphasia that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 63 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06968663, a Phase 2 study of Stroke and Aphasia, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to determine if Transcranial Magnetic Stimulation (TMS) combined with modified Constraint Induced Language Therapy (mCILT) is an effective treatment for aphasia when delivered in the subacute stage after stroke. The main questions this study aims to answer are: 1. Can TMS combined with mCILT improve overall speech? 2. Can we identify specific behavioral and biological characteristics that would benefit most from the TMS and mCILT treatment? Researchers will compare real TMS to sham (fake) TMS to see whether TMS can treat subacute aphasia. Importantly, this trial will use electric field guided TMS to identify optimal and individualized stimulation intensity and site targeting. Participants will: * Complete a screening and medical intake to determine eligibility * Undergo MRI scans * Participate in 10 consecutive sessions (Monday-Friday) of TMS and mCILT treatment * Complete follow-up assessments immediately and 4 months after treatment
Primary Outcome
Change in performance on the Western Aphasia Battery (WAB-AQ score). WAB AQ Score is out of 100, where a higher score means less language impairment.
Conditions Studied
Interventions
- DEVICE Transcranial Magnetic Stimulation (TMS)
- BEHAVIORAL Modified Constraint Induced Language Therapy (mCILT)
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2024-08-01 |
| Est. Completion | 2029-07-31 |
| Phase | Phase 2 |
What NCT06968663 shows while recruiting
NCT06968663 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Stroke appearing as the primary indexed condition, and to 2 interventions - of which Transcranial Magnetic Stimulation (TMS) is the first listed.
NCT06968663 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06968663 about?
NCT06968663 is a clinical study titled "Transcranial Magnetic Stimulation + Language Therapy to Treat Subacute Aphasia". The goal of this clinical trial is to determine if Transcranial Magnetic Stimulation (TMS) combined with modified Constraint Induced Language Therapy (mCILT) is an effective treatment for aphasia when delivered in the subacute stage after stroke. The main questions this study aims to answer are: 1...
What is the current status of trial NCT06968663?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2024-08-01. Estimated completion is 2029-07-31.
What conditions does trial NCT06968663 study?
This clinical trial studies the following conditions: Stroke, Aphasia, Aphasia Following Cerebral Infarction.
What interventions are being tested in trial NCT06968663?
The interventions under investigation include: Transcranial Magnetic Stimulation (TMS) (DEVICE), Modified Constraint Induced Language Therapy (mCILT) (BEHAVIORAL).
Who is sponsoring clinical trial NCT06968663?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06968663 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06968663's enrollment target sits among peer trials
63 201st of 454 higher than 252 of 454 other Stroke trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease
RECRUITING · Phase 2
-
Balancing Effortful and Errorless Learning in Naming Treatment for Aphasia
RECRUITING · Phase 2
-
Transcranial Magnetic Stimulation + Language Therapy to Treat Mild Aphasia
RECRUITING · Phase 2
-
Novel Wrist Sensor System to Promote Hemiparetic Arm Use in Home Daily Life of Chronic Stroke Survivors
RECRUITING · Phase 2
-
Myofascial Dysfunction in Post Stroke Shoulder Pain
RECRUITING · Phase 2
-
Escitalopram and Language Intervention for Subacute Aphasia
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI